NCT07104799 - Momelotinib During and After HCT in Myelofibrosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2026

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2030

Conditions

MyelofibrosisHematopoietic Cell Transplantation (HCT)

Interventions

DRUG

Momelotinib

Administered orally once per day during each 28-day cycle. This will start on day -7 (7 days before HCT) and continue for up to 13 cycles. Dose cohorts (100 mg daily, 150 mg daily, 200 mg daily) will be investigated in the peri-transplant period. Once participants have achieved hematopoietic recovery and are at least Day 21 after HCT, participants will increase the dose to 200 mg daily.

Trial Locations (1)

02114

Massachusetts General Hospital, Boston